IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes.

about

IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes.

Item

http://www.wikidata.org/entity/Q55361133

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

IRAK1 expression in bone marro ...... in myelodysplastic syndromes.

@en

IRAK1 expression in bone marro ...... in myelodysplastic syndromes.

@nl

type

Item

label

IRAK1 expression in bone marro ...... in myelodysplastic syndromes.

@en

IRAK1 expression in bone marro ...... in myelodysplastic syndromes.

@nl

prefLabel

IRAK1 expression in bone marro ...... in myelodysplastic syndromes.

@en

IRAK1 expression in bone marro ...... in myelodysplastic syndromes.

@nl

P1476

IRAK1 expression in bone marro ...... s in myelodysplastic syndromes

@en

P2093

Fernando Ferreira Costa

http://www.w3.org/2001/XMLSchema#string

Paula de Melo Campos

http://www.w3.org/2001/XMLSchema#string

Sara Teresinha Olalla Saad

http://www.w3.org/2001/XMLSchema#string

P2860

Toll-like receptor signalling

NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Toll-like receptor alterations in myelodysplastic syndrome

Revised international prognostic scoring system for myelodysplastic syndromes.

Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes.

Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells.

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.

P304

92-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BJHH.2017.10.001

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

João Agostinho Machado-Neto

Fabiola Traina

I Lorand-Metze

P577

2017-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29519376

http://www.w3.org/2001/XMLSchema#string

P932

6003099

http://www.w3.org/2001/XMLSchema#string